Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.

  • Kate Young, Elizabeth Smyth, Ian Yin-Yan Chau
  • Published 2015 in Therapeutic advances in gastroenterology

Abstract

Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.

DOI: 10.1177/1756283X15592586

Cite this paper

@article{Young2015RamucirumabFA, title={Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.}, author={Kate Young and Elizabeth Smyth and Ian Yin-Yan Chau}, journal={Therapeutic advances in gastroenterology}, year={2015}, volume={8 6}, pages={373-83} }